162 related articles for article (PubMed ID: 30039195)
1. Ascites IL-10 Promotes Ovarian Cancer Cell Migration.
Lane D; Matte I; Garde-Granger P; Bessette P; Piché A
Cancer Microenviron; 2018 Dec; 11(2-3):115-124. PubMed ID: 30039195
[TBL] [Abstract][Full Text] [Related]
2. CCL18 from ascites promotes ovarian cancer cell migration through proline-rich tyrosine kinase 2 signaling.
Lane D; Matte I; Laplante C; Garde-Granger P; Carignan A; Bessette P; Rancourt C; Piché A
Mol Cancer; 2016 Sep; 15(1):58. PubMed ID: 27613122
[TBL] [Abstract][Full Text] [Related]
3. Decreased IL-1 RA concentration in ascites is associated with a significant improvement in overall survival in ovarian cancer.
Mustea A; Pirvulescu C; Könsgen D; Braicu EI; Yuan S; Sun P; Lichtenegger W; Sehouli J
Cytokine; 2008 Apr; 42(1):77-84. PubMed ID: 18329282
[TBL] [Abstract][Full Text] [Related]
4. Expression of IL-10 in patients with ovarian carcinoma.
Mustea A; Könsgen D; Braicu EI; Pirvulescu C; Sun P; Sofroni D; Lichtenegger W; Sehouli J
Anticancer Res; 2006; 26(2C):1715-8. PubMed ID: 16617566
[TBL] [Abstract][Full Text] [Related]
5. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
Matte I; Garde-Granger P; Bessette P; Piché A
BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between interleukin-10 level in ascites of patients with primary ovarian epithelial carcinoma and immune defect in peritoneal cavity].
Zhou JW; Cheng Q; Xie X; Chen HZ; Ye DF; Lu WG
Ai Zheng; 2004 May; 23(5):573-6. PubMed ID: 15142457
[TBL] [Abstract][Full Text] [Related]
7. Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients.
Yang Q; Bae G; Nadiradze G; Castagna A; Berezhnoy G; Zizmare L; Kulkarni A; Singh Y; Weinreich FJ; Kommoss S; Reymond MA; Trautwein C
J Transl Med; 2022 Dec; 20(1):581. PubMed ID: 36503580
[TBL] [Abstract][Full Text] [Related]
8. Stem-like tumor cells and proinflammatory cytokines in the ascitic fluid of ovarian cancer patients.
Gening SO; Abakumova TV; Antoneeva II; Rizvanov AA; Gening TP; Gafurbaeva DU
Klin Lab Diagn; 2021 May; 66(5):297-303. PubMed ID: 34047516
[TBL] [Abstract][Full Text] [Related]
9. Stress hormones are associated with inflammatory cytokines and attenuation of T-cell function in the ascites from patients with high grade serous ovarian cancer.
Aquino-Acevedo AN; Knochenhauer H; Castillo-Ocampo Y; Ortiz-León M; Rivera-López YA; Morales-López C; Cruz-Robles ME; Hernández-Cordero ER; Russell S; Whitaker R; Bonilla-Claudio M; Chen DT; Dutil J; Gaillard SL; Yi JS; Previs RA; Armaiz-Pena GN
Brain Behav Immun Health; 2022 Dec; 26():100558. PubMed ID: 36439058
[TBL] [Abstract][Full Text] [Related]
10. Ovarian cancer ascites enhance the migration of patient-derived peritoneal mesothelial cells via cMet pathway through HGF-dependent and -independent mechanisms.
Matte I; Lane D; Laplante C; Garde-Granger P; Rancourt C; Piché A
Int J Cancer; 2015 Jul; 137(2):289-98. PubMed ID: 25482018
[TBL] [Abstract][Full Text] [Related]
11. Inflammation-regulating factors in ascites as predictive biomarkers of drug resistance and progression-free survival in serous epithelial ovarian cancers.
Lane D; Matte I; Garde-Granger P; Laplante C; Carignan A; Rancourt C; Piché A
BMC Cancer; 2015 Jul; 15():492. PubMed ID: 26122176
[TBL] [Abstract][Full Text] [Related]
12. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
[TBL] [Abstract][Full Text] [Related]
13. Peritoneal NK cells are responsive to IL-15 and percentages are correlated with outcome in advanced ovarian cancer patients.
Hoogstad-van Evert JS; Maas RJ; van der Meer J; Cany J; van der Steen S; Jansen JH; Miller JS; Bekkers R; Hobo W; Massuger L; Dolstra H
Oncotarget; 2018 Oct; 9(78):34810-34820. PubMed ID: 30410679
[TBL] [Abstract][Full Text] [Related]
14. Profiling of cytokines in human epithelial ovarian cancer ascites.
Matte I; Lane D; Laplante C; Rancourt C; Piché A
Am J Cancer Res; 2012; 2(5):566-80. PubMed ID: 22957308
[TBL] [Abstract][Full Text] [Related]
15. Ascites-derived IL-6 and IL-10 synergistically expand CD14
Wu L; Deng Z; Peng Y; Han L; Liu J; Wang L; Li B; Zhao J; Jiao S; Wei H
Oncotarget; 2017 Sep; 8(44):76843-76856. PubMed ID: 29100353
[TBL] [Abstract][Full Text] [Related]
16. Microparticles from ovarian carcinomas are shed into ascites and promote cell migration.
Press JZ; Reyes M; Pitteri SJ; Pennil C; Garcia R; Goff BA; Hanash SM; Swisher EM
Int J Gynecol Cancer; 2012 May; 22(4):546-52. PubMed ID: 22315094
[TBL] [Abstract][Full Text] [Related]
17. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
[TBL] [Abstract][Full Text] [Related]
18. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
[TBL] [Abstract][Full Text] [Related]
20. In vivo tumor growth of high-grade serous ovarian cancer cell lines.
Mitra AK; Davis DA; Tomar S; Roy L; Gurler H; Xie J; Lantvit DD; Cardenas H; Fang F; Liu Y; Loughran E; Yang J; Sharon Stack M; Emerson RE; Cowden Dahl KD; V Barbolina M; Nephew KP; Matei D; Burdette JE
Gynecol Oncol; 2015 Aug; 138(2):372-7. PubMed ID: 26050922
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
